On Tuesday, Argus reiterated its “buy” rating for MRK stock, and Toung said Lynparza has sweetened the deal. Pharmaceutical giant Merck already has a major growth driver in its Keytruda cancer treatment, and Toung sees even …
Investors in Merck & Co., Inc. MRK need to pay close attention to the stock based on moves in the options market lately. That is because the Dec 1, 2017 $65 Call had some of the highest implied volatility of all equity options today. Implied …
3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 …
A month has gone by since the last earnings report for Merck & Company, Inc. MRK. Shares have added about 2.3% in that time frame, outperforming the market. Will the recent positive trend continue leading up to the stock's next …
On April 5, 2018, Barclays (BCS) updated its recommendation for Merck (MRK) to “overweight” from “equal weight,” and Barclays analyst Geoff Meacham raised its target price from $62 to $64. Merck stock rose ~1% during the day but …
Merck & Co., Inc. MRK will be reporting second-quarter 2017 earnings on Jul ... show that Merck is likely to beat on earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 …
Merck’s MRK Keytruda has hit a stumbling block with the FDA placing three combination studies on clinical hold. …